Alfuzosin Hydrochloride Tablet, Film Coated, Extended Release
Product Images NDC 51655-087

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Alfuzosin Hydrochloride (NDC 51655-087). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Northwind Health Company, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Label (51655 087 52)

Label (51655 087 52)
Label for Alfuzosin Hydrochloride extended-release film-coated tablets, USP 10 mg, containing 30 tablets. The label indicates the product is prescription only, with storage instructions and packaging details. The labeler is Northwind Health Company, LLC.*
FDA Label Image

Figure 1 (Alfuzosin Fig1)

Figure 1 (Alfuzosin Fig1)
A line graph showing mean alfuzosin plasma concentration (ng/mL) over a 24-hour period after a single 10 mg extended-release tablet dose in healthy middle-aged male volunteers under fed and fasted conditions. The graph compares plasma levels, with higher concentrations observed in the fed state compared to the fasted state over time.*
FDA Label Image

Figure 2 — Mean Change From Baseline In Ipss Total Symptom Score: Trial 1 (Alfuzosin Fig2)

Figure 2 — Mean Change From Baseline In Ipss Total Symptom Score: Trial 1 (Alfuzosin Fig2)
A line graph showing mean change from baseline in IPSS Total Symptom Score over 84 days of treatment comparing Alfuzosin Hydrochloride and placebo groups. The x-axis represents days of treatment (0, 28, 56, 84), and the y-axis shows mean change values. The Alfuzosin group shows a greater negative mean change compared to placebo over time, with significant difference indicated (p < 0.001).*
FDA Label Image

Figure 3 — Mean Change From Baseline In Ipss Total Symptom Score: Trial 2 (Alfuzosin Fig3)

Figure 3 — Mean Change From Baseline In Ipss Total Symptom Score: Trial 2 (Alfuzosin Fig3)
A line graph showing mean change from baseline in IPSS Total Symptom Score over 84 days of treatment, comparing placebo (N=152) and Alfuzosin Hydrochloride (N=137) groups. The graph depicts a greater reduction in symptom score for the Alfuzosin Hydrochloride group throughout the treatment period.*
FDA Label Image

Figure 4 — Mean Change From Baseline In Ipss Total Symptom Score: Trial 3 (Alfuzosin Fig4)

Figure 4 — Mean Change From Baseline In Ipss Total Symptom Score: Trial 3 (Alfuzosin Fig4)
A line graph depicting mean change from baseline in IPSS Total Symptom Score over 84 days of treatment. Two groups are shown: placebo (triangles) and Alfuzosin Hydrochloride (squares). The Alfuzosin group shows a greater decrease in symptom score over time compared to placebo.*
FDA Label Image

Figure 5 — Mean Change From Baseline In Peak Urine Flow Rate (ml/s): Trial 1 (Alfuzosin Fig5)

Figure 5 — Mean Change From Baseline In Peak Urine Flow Rate (ml/s): Trial 1 (Alfuzosin Fig5)
A line graph showing the mean change from baseline in peak urine flow rate (mL/s) over 84 days of treatment comparing Alfuzosin Hydrochloride to placebo. The x-axis represents days of treatment (0, 28, 56, 84), and the y-axis shows mean change in mL/s. Alfuzosin Hydrochloride shows a significant increase compared to placebo throughout the treatment period.*
FDA Label Image

Figure 6 — Mean Change From Baseline In Peak Urine Flow Rate (ml/s): Trial 2 (Alfuzosin Fig6)

Figure 6 — Mean Change From Baseline In Peak Urine Flow Rate (ml/s): Trial 2 (Alfuzosin Fig6)
A line graph showing the mean change from baseline in peak urine flow rate (mL/s) over days of treatment in Trial 2. It compares two groups: one treated with placebo and the other with Alfuzosin Hydrochloride. The graph shows data points at multiple time intervals up to 84 days, with Alfuzosin Hydrochloride demonstrating a greater increase than placebo.*
FDA Label Image

Figure 7 — Mean Change From Baseline In Peak Urine Flow Rate (ml/s): Trial 3 (Alfuzosin Fig7)

Figure 7 — Mean Change From Baseline In Peak Urine Flow Rate (ml/s): Trial 3 (Alfuzosin Fig7)
A line graph showing mean change from baseline in peak urine flow rate (mL/s) over days of treatment for two groups: placebo and Alfuzosin Hydrochloride. The x-axis represents days of treatment (0, 14, 28, 56, 84), and the y-axis shows mean change in mL/s. The graph compares changes over time between the placebo group and the Alfuzosin Hydrochloride group.*
FDA Label Image

Chemical Structure (Alfuzosin Str)

Chemical Structure (Alfuzosin Str)
Chemical structure of alfuzosin hydrochloride showing its molecular components and arrangement, including aromatic rings, nitrogen atoms, and functional groups typical of the active ingredient alfuzosin hydrochloride.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.